The MANEUVER trial was a global, randomized, double-blind, placebo-controlled study evaluating pimicotinib in unresectable TGCT patients. Pimicotinib shows promising long-term efficacy in treating ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback